QYUNS THERAPEUTICS CO., LTD. Qyuns Therapeutics Co., Ltd. Share Price
Equities
2509
CNE1000069W9
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 29.2 HKD | +1.04% |
|
+10.82% | 0.00% |
| Sales 2022 | 9.66M 1.34M 10.44M 106M | Sales 2023 | 14.75M 2.04M 15.93M 162M | Capitalization | 5.94B 821M 6.42B 65.26B |
|---|---|---|---|---|---|
| Net income 2022 | -298M -41.2M -322M -3.27B | Net income 2023 | -508M -70.24M -549M -5.58B | EV / Sales 2022 * | - |
| Net cash position 2022 * | - 0 0 0 | Net cash position 2023 * | - 0 0 0 | EV / Sales 2023 * | - |
| P/E ratio 2022 * |
-
| P/E ratio 2023 * |
-
| Employees | 331 |
| Yield 2022 * |
-
| Yield 2023 * |
-
| Free-Float | 13.21% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.04% | ||
| 1 week | +10.82% | ||
| Current month | +27.79% | ||
| 1 month | +26.68% |
1 week
25.70
29.45
1 month
21.9029.45
Current year
18.1429.45
1 year
18.1429.45
3 years
18.1429.45
5 years
18.1429.45
10 years
18.1429.45
Qyuns Therapeutics Co Ltd is a China-based company mainly engaged in biopharmaceuticals. The Company is mainly engaged in biotechnology research and development of biological therapies for autoimmune and allergic diseases. The Company's business mainly covers four major disease areas, including skin, rheumatism, respiratory and digestive tract diseases. The Company is developing eight projects, with target indications including psoriasis, atopic dermatitis, rheumatoid arthritis, inflammatory bowel disease and asthma. The Company's core products include QX002N and QX005N.
| 1st Jan change | Capi. | |
|---|---|---|
| 0.00% | 821M | |
| +5.33% | 111B | |
| +12.11% | 105B | |
| -12.56% | 22.34B | |
| -3.70% | 21.93B | |
| -6.03% | 18.59B | |
| -35.21% | 18.12B | |
| -10.86% | 16.96B | |
| +5.10% | 13.7B | |
| +37.57% | 12.45B |
- Stock Market
- Equities
- 2509 Stock
